PRL-8-53 is a nootropic research chemical derived from benzoic acid and phenylmethylamine (Benzylamine) that has been shown to act as a hypermnesic drug in humans; it was first synthesized by medical chemistry professor Nikolaus Hansl at Creighton University in the 1970s as part of his work on amino ethyl meta benzoic acid esters.
A single study in humans was reported in 1978. The double-blind trial of PRL-8-53 in 47 healthy volunteers measured its effects on a variety of cognitive measures. 5 mg of the drug was administered orally 2–2.5 hours before the study tasks. Overall improvements in recollection differed based on how many words were recalled under placebo, with the poor performers (six words or fewer) experiencing a 87.5-105% increase in recollection and the high performers (eight or more words) a 7.9-14% increase which failed to reach statistical significance; when controlling for subjects over the age of 30 only, a 108-152% increase was noted. No side effects were reported during the trial.
The exact mechanism of action of PRL-8-53 remains unknown. Doses up to 200 mg/kg are not observed to have stimulant properties, and a dosage of 20 mg/kg did not exhibit side effects in rats. It displays possible cholinergic properties, and potentiates dopamine while partially inhibiting serotonin. PRL-8-53 reverses the catatonic and ptotic effects of reserpine.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS INTENDED FOR RESEARCH PURPOSES ONLY. YOU MUST BE AT LEAST 18 YEARS OLD TO PURCHASE THIS PRODUCT.
THIS PRODUCT HAS NOT BEEN APPROVED FOR HUMAN CONSUMPTION, AND IS FOR SALE ON THE CONDITION THAT IT BE USED FOR RESEARCH PURPOSES ONLY